<DOC>
	<DOCNO>NCT01640691</DOCNO>
	<brief_summary>The objective single arm study evaluate immune response safety profile two injection inactivate whole-virion vaccine contain aluminum hydroxide adjuvant , AdimFlu-W ( H5N1 ) , influenza A ( H5N1 ) healthy adult .</brief_summary>
	<brief_title>Immunogenicity Safety Pandemic Influenza Vaccine Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male nonpregnant female ( indicated negative urine pregnancy test immediately day prior first vaccine administration ) 20 60 year age time first vaccination . Women childbearing potential agree practice highly effective birth control throughout study ( Screening Month 3 ) . Subjects free obvious health problem judge investigator ( establish medical history physical examination ) enter study . Subject physically mentally capable participate study willing adhere study procedure complete element study diary . Subjects provide sign informed consent receive detailed explanation study protocol prior study procedure . Medical history physicianconfirmed infection H5N1 virus history vaccination H5N1 influenza vaccine . Subject high risk contract H5N1 influenza infection ( e.g . poultry worker ) . Has receive license vaccine within 2 week inactivate vaccine 4 week live vaccine prior enrollment study . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Subject use oral parenteral steroid , highdose inhaled steroid ( &gt; 800 mcg/day beclomethasone dipropionate equivalent ) immunosuppressive cytotoxic drug within 30 day precede first dose study vaccine . Subject receive blood transfusion immunoglobulin within 90 day prior first dose study vaccine , plan administration blood product study period . Subject know allergy egg component study vaccine . Subject history severe allergic reaction anaphylaxis . Subject history GuillainBarr√© Syndrome . Subject acute illness temperature great 38.0 degree Celsius method within 3 day prior vaccination . Subject confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection . Subject rash , dermatologic condition tattoo may interfere injection site reaction rating . Evidence substance ( alcohol drug ) abuse neurological psychiatric diagnosis , even clinically stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Subjects abnormal laboratory result screen : ( 1 ) ALT AST &gt; = 1 x upper limit normal ( ULN ) . ( 2 ) Creatinine &gt; = 1 x ULN . ( 3 ) Any significant laboratory abnormality judge investigator Females know pregnancy positive urine betahuman chorionic gonadotropin test result prior first study vaccine dose , lactate nursing . Subject condition disqualifies his/her participation study opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>pandemic influenza</keyword>
	<keyword>pandemic influenza vaccine</keyword>
	<keyword>Influenza</keyword>
	<keyword>Orthomyxoviruses</keyword>
	<keyword>A/H5N1</keyword>
</DOC>